Consolidated Statement Of Cash Flows

Carna Biosciences, Inc. - Filing #7313273

Concept 2024-01-01 to
2024-06-30
As at
2024-06-30
As at
2023-12-31
2023-01-01 to
2023-06-30
As at
2023-06-30
As at
2022-12-31
Consolidated statement of cash flows
Statement of cash flows
Cash flows from operating activities
Subtotal
-214,624,000 JPY
-918,919,000 JPY
Interest paid
-1,665,000 JPY
-1,650,000 JPY
Net cash provided by (used in) operating activities
-222,059,000 JPY
-938,544,000 JPY
Cash flows from investing activities
Purchase of property, plant and equipment
-7,108,000 JPY
-6,854,000 JPY
Net cash provided by (used in) investing activities
-7,108,000 JPY
-6,854,000 JPY
Cash flows from financing activities
Repayments of long-term borrowings
-59,994,000 JPY
-59,994,000 JPY
Redemption of bonds
JPY
-14,014,000 JPY
Net cash provided by (used in) financing activities
279,068,000 JPY
1,222,158,000 JPY
Other, net
-3,636,000 JPY
JPY
Effect of exchange rate change on cash and cash equivalents
87,029,000 JPY
28,818,000 JPY
Net increase (decrease) in cash and cash equivalents
136,929,000 JPY
305,577,000 JPY
Cash and cash equivalents
3,026,030,000 JPY
2,889,101,000 JPY
3,684,625,000 JPY
3,379,048,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.